NCT05576532 is a Phase 2 clinical trial of BCL2 Inhibitor plus IM2 regimen in T-lymphoblastic Lymphoma, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT05576532?

Interventions in NCT05576532: BCL2 Inhibitor plus IM2 regimen.

What condition does NCT05576532 study?

NCT05576532 studies T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma, Refractory Leukemia, Safety, Efficacy, Self.

Is NCT05576532 still recruiting?

NCT05576532 is currently status unknown. Last updated 28 June 2023.

Last reviewed 2023-06-28 · How we verify

NCT05576532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Status unknown Phase 2 Last updated 28 June 2023

What this trial tests

Phase 2 trial testing BCL2 Inhibitor plus IM2 regimen in T-lymphoblastic Lymphoma in 30 participants. Status unknown.

Timeline

10 January 2023

Primary endpoint
10 October 2024

10 October 2025

Quick facts

Lead sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	10 January 2023
Primary completion	10 October 2024
Estimated completion	10 October 2025
Sites	1 location across China

Drugs / interventions tested

BCL2 Inhibitor plus IM2 regimen — full drug profile →

Conditions studied

T-lymphoblastic Lymphoma — all drugs for T-lymphoblastic Lymphoma →
Relapsed Disease — all drugs for Relapsed Disease →
Refractory Lymphoma — all drugs for Refractory Lymphoma →
Refractory Leukemia — all drugs for Refractory Leukemia →

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 14 to 45, any sex, with T-lymphoblastic Lymphoma or Relapsed Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of Venetoclax plus IM2 regimen for relapsed and refractory T lymphoblastic lymphoma/leukemia. Dosage of Venetoclax:100mg/d-400mg/d(dose adjustment when concomitant used with CYP3A inhibitor) for 1-28 days (at least 7 days); IM2 regimen: Ifosfamide 1-1.5g/m2/d for 5 days; Mitoxantrone 6-8g/m2/d for 3 days( or Liposome mitoxantrone 20mg/m2 d1 or Idarubicin 6-8mg/m2/d for 3 days) ;methotrexate 1-1.5g/m2/d for 1 day;

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.
Domingues C, Jarak I, Veiga F, Dourado M, et al · · 2023 · cited 33× · PMID 37896191 · DOI 10.3390/pharmaceutics15102431
Mitochondria and Acute Leukemia: A Clinician's Perspective.
Iyer P, Jasdanwala SS, Bhatia K, Bhatt S. · · 2024 · cited 6× · PMID 39273651 · DOI 10.3390/ijms25179704
B-Cell Lymphoma 2 Inhibition in Acute Lymphoblastic Leukemia: Mechanisms, Resistance, and Emerging Combinations With Venetoclax.
Hanbali A, Kotb A, Saleh M. · · 2025 · cited 1× · PMID 40904937 · DOI 10.14740/jh2092
The use of venetoclax in the treatment of acute lymphoblastic leukemia-a systematic review.
Kowalczyk A, Zarychta J, Zawitkowska J, Lejman M. · · 2026 · PMID 41523908 · DOI 10.1177/17588359251403912

Verify or expand the search:

Other recruiting trials for T-lymphoblastic Lymphoma

Currently open trials in the same condition.

NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
NCT06633341 — Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma · EARLY_PHASE1 · recruiting
NCT06376721 — Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT06136364 — CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study · Phase 1 · recruiting

Other Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT06667466 — New Laser and Suction Sheath for Kidney Stone Treatment · not yet recruiting
NCT07043374 — Impact of Humid-Heat on Gut-Tryptophan-Stone Pathway · not yet recruiting
NCT07415226 — Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT07439120 — Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05576532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 28 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05576532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing